Considering the mechanisms of synergy between chemotherapy and immunotherapy, sequential approaches might be helpful (7), and there was a retrospective study that showed that administering PD-1/PD-L1 inhibitors 1–10 days (especially 3–5 days) after chemotherapy is superior to administering PD-1/PD-L1 inhibitors before or concurrent with chemotherapy in patients with refractory lung cancer (22). The gene discussed is CD274; the disease is lung cancer.